Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 258 results found since Jan 2013.
The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy.
In conclusion, the combination nanoparticle with checkpoint blockade cancer immunity is a promising direction that may fulfill the requirement of cancer treatment.
PMID: 30406152 [PubMed - in process]
Source: Journal of Immunology Research - November 9, 2018 Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease
Regulatory T cells (Tregs) are critical for maintaining immune homeostasis. However, current Treg immunotherapies do not optimally treat inflammatory diseases in patients. Understanding the cellular processes that control Treg function may allow for the augmentation of therapeutic efficacy. In contrast to activated conventional T cells, in which protein kinase C-θ (PKC-θ) localizes to the contact point between T cells and antigen-presenting cells, in human and mouse Tregs, PKC-θ localizes to the opposite end of the cell in the distal pole complex (DPC). Here, using a phosphoproteomic screen, we identified the intermedia...
Source: Journal of Clinical Investigation - September 18, 2018 Category: Biomedical Science Authors: Cameron McDonald-Hyman, James T. Muller, Michael Loschi, Govindarajan Thangavelu, Asim Saha, Sudha Kumari, Dawn K. Reichenbach, Michelle J. Smith, Guoan Zhang, Brent H. Koehn, Jiqiang Lin, Jason S. Mitchell, Brian T. Fife, Angela Panoskaltsis-Mortari, Col Source Type: research
Signal transducer and activator of transcription 3 downregulation in J774A.1 cell line as a model of M2 macrophages in tumor microenvironment
Conclusion: The expression of STAT3 in J774A.1 cells confirmed that these cells are M2 macrophage. Moreover, silencing of STAT3 by siRNA delivery using oligofectamine delivery suggests that siRNA delivery using vehicles like nanoliposome could be a useful therapeutic agent in M2 macrophage therapy and its switch to M1 macrophages. This approach could be considered as a novel therapeutic agent for the treatment of all cancers.
Source: Journal of Cancer Research and Therapeutics - September 7, 2018 Category: Cancer & Oncology Authors: Zahra Seyedi Mohammad Reza Hashemzadeh Abasalt Hosseinzadeh Colagar Mahmoud Reza Jaafari Source Type: research
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
This study implicates that a combination therapy targeting MYC function and PD-L1/PD-1 pathway might be effective for treatment of HCC.
Source: Molecular Immunology - July 10, 2018 Category: Allergy & Immunology Source Type: research
Targeted Delivery of siRNA Therapeutics Using Ligand Mediated Biodegradable Polymeric Nanocarriers.
CONCLUSION: In this review, we provide ⅰ) an overview of the non-viral carrier associated with siRNA delivery for cancer treatment, and ⅱ) a description of the five major cancer-targeting ligands.
PMID: 29962332 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - July 1, 2018 Category: Drugs & Pharmacology Authors: Jin HS, Soo CK, Hye AM, Sukdeb P, Pill-Hoon C, Sangshetti J, Arote RB Tags: Curr Pharm Des Source Type: research
The siRNA ‐mediated downregulation of PD‐1 alone or simultaneously with CTLA‐4 shows enhanced in vitro CAR‐T‐cell functionality for further clinical development towards the potential use in immunotherapy of melanoma
Experimental Dermatology,Volume 27, Issue 7, Page 769-778, July 2018.
Source: Experimental Dermatology - June 28, 2018 Category: Dermatology Authors: Bianca
Simon
,
Dennis C.
Harrer
,
Beatrice
Schuler ‐Thurner
,
Niels
Schaft
,
Gerold
Schuler
,
Jan
Dörrie
,
Ugur
Uslu Source Type: research
Nanopharmaceuticals and Their Applications in Bladder Cancer Therapy: a Mini Review
The primary treatment for high-grade non-muscle invasive bladder cancer (NMIBC) is based on surgery by transurethral resection of bladder tumor (TURBT), followed by intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) to prevent recurrence and to reduce the tumor progression. However, BCG therapy shows several undesirable effects. The current treatment on NMIBC is doxorubicin (DOX), but with high toxicity. Our nanotechnology strategy was done through scaffolds for the NMIBC treatment: graphene oxide (GO) and a nanostructured lipid carrier (NLC). A GO hybrid for administration of DOX and small interfering RNA (siR...
Source: Journal of the Brazilian Chemical Society - May 7, 2018 Category: Chemistry Source Type: research
The siRNA ‐mediated downregulation of PD‐1 alone or simultaneously with CTLA‐4 shows enhanced in‐vitro CAR‐T cell functionality for further clinical development towards the potential use in immunotherapy of melanoma
Experimental Dermatology,Volume 0, Issue ja, -Not available-.
Source: Experimental Dermatology - April 28, 2018 Category: Dermatology Authors: Bianca Simon
,
Dennis C Harrer
,
Beatrice Schuler ‐Thurner
,
Niels Schaft
,
Gerold Schuler
,
Jan Dörrie
,
Ugur Uslu Source Type: research
EBV transformation induces overexpression of hMSH2/3/6 on B lymphocytes and enhances γδT cell-mediated cytotoxicity via TCR and NKG2D.
This article is protected by copyright. All rights reserved.
PMID: 29512904 [PubMed - as supplied by publisher]
Source: Immunology - March 7, 2018 Category: Allergy & Immunology Authors: Yu-Mei D, Liu HY, Liu YF, Zhang Y, He W Tags: Immunology Source Type: research
Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck.
This study suggests that chromatin modifiers contribute to CD8+ T-cell exclusion and antigen presentation capacity of HPV-negative SCCHN, supporting that targeting of specific PMTs and/or PDMTs could enhance CD8+ T-cell infiltration and increase the proportion of patients that may benefit from immunotherapy.
PMID: 29348866 [PubMed]
Source: Oncotarget - January 21, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma
ConclusionsOur findings clearly demonstrate the roles of eIF4E in RCC growth, survival, metastasis and resistance. Ribavirin is an antiviral drug, and its clinical efficacy is currently being investigated in the treatment of various cancers. Our findings support and provide a preclinical evidence for clinical trial for the combination of ribavirin with chemo-/immunotherapy in RCC.
Source: Clinical and Translational Oncology - October 30, 2017 Category: Cancer & Oncology Source Type: research
Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
CONCLUSIONS: PD-L1 expression was associated with poor survival of gastric cancer, and HER2 signaling affects the expression of PD-L1 in gastric cancer. In gastric cancer, PTEN and HER2 are potential candidate biomarkers for developing human antibodies that block PD-L1.
PMID: 28910818 [PubMed - as supplied by publisher]
Source: Oncology - September 15, 2017 Category: Cancer & Oncology Authors: Oki E, Okano S, Saeki H, Umemoto Y, Teraishi K, Nakaji Y, Ando K, Zaitsu Y, Yamashita N, Sugiyama M, Nakashima Y, Ohgaki K, Oda Y, Maehara Y Tags: Oncology Source Type: research
Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma
Conclusions: PD-L1 expression was associated with poor survival of gastric cancer, and HER2 signaling affects the expression of PD-L1 in gastric cancer. In gastric cancer, PTEN and HER2 are potential candidate biomarkers for developing human antibodies that block PD-L1.Oncology
Source: Oncology - September 14, 2017 Category: Cancer & Oncology Source Type: research
Zerumbone modulates CD1d expression and lipid antigen presentation pathway in breast cancer cells.
This study shows that, CD1d overexpression is associated with the progressive stages of breast cancer and ZER could be an adjuvant to potentiate cancer immunotherapy.
PMID: 28633979 [PubMed - as supplied by publisher]
Source: Toxicology in Vitro - June 17, 2017 Category: Toxicology Authors: Shyanti RK, Sehrawat A, Singh SV, Mishra JPN, Singh RP Tags: Toxicol In Vitro Source Type: research
